Romosozumab Followed by Alendronate Superior in Reducing Fracture Risk

By September 12, 2017

ARCH (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture) was a multicenter, international, randomized, double-blind, alendronate-controlled study (n=4,093) in postmenopausal women with osteoporosis at high risk for fracture based on previous fracture history.

Fracture Risk Reduced with Abaloparatide Followed by Alendronate

By September 11, 2017

The data showed a statistically significant fracture risk reduction through 3.5 years.

Fulranumab for Osteoarthritis Pain

By March 08, 2017

Sanga, Panna MD et al. "Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study"

New Position Paper on Screening for Osteoporosis Therapy Adherence Published

By January 30, 2017

The International Osteoporosis Foundation and European Calcified Tissue Society Working Group proposed a screening strategy measuring certain bone turnover markers in patients who have initiated oral bisphosphonate therapy for postmenopausal osteoporosis as a practical way to identify low adherence.

Denosumab Prevents Osteoporosis in Autoimmune Liver Diseases

By November 11, 2016

Denosumab injections prevent osteoporosis in patients with primary biliary cholangitis and autoimmune hepatitis, with few adverse effects.